Filing Overview
Xeris Biopharma Holdings, Inc. filed a Form 8-K on June 8, 2022, reporting the results of its Annual Meeting of Stockholders held that day. The filing covers governance matters and does not provide quarterly or annual financial results.
Business Context and Reporting Period
- Record date: April 12, 2022.
- Common shares outstanding and entitled to vote: 135,528,195.
- The company is an emerging growth company and its common stock trades on Nasdaq under the symbol XERS.
Meeting Results
Election of Class I Directors
Stockholders approved the election of BJ Bormann, Garheng Kong, and John Schmid to serve until the 2025 Annual Meeting and until their successors are elected and qualified.
| Nominee | For | Withhold | Broker Non-Votes |
|---|---|---|---|
| BJ Bormann | 41,468,315 | 6,255,170 | 32,110,653 |
| Garheng Kong | 46,352,854 | 1,370,631 | 32,110,653 |
| John Schmid | 41,520,265 | 6,203,220 | 32,110,653 |
Ratification of Independent Auditor
Stockholders approved the ratification of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.
| For | Against | Abstain |
|---|---|---|
| 79,036,677 | 687,062 | 110,399 |
Financial Metrics and Material Changes
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other operating metrics. It does not report material changes versus a prior comparable period.
Outlook, Risks, and Unusual Items
No management outlook, risk update, contingencies, or unusual financial items are disclosed in this filing. No matters other than the director elections and auditor ratification were submitted to a vote.
Investor Verification Items
- Verify the director election terms and board composition in subsequent filings.
- Confirm KPMG LLP’s appointment and any subsequent changes in the company’s independent auditor.
- Review the company’s financial statements and subsequent filings for revenue, liquidity, debt, cash-burn, and operating updates, which are not included in this 8-K.
- Consider the effect of broker non-votes and the difference between shares outstanding and votes cast on governance proposals.